The U.S. Food and Drug Administration today issued a final guidance for industry, Postapproval Pregnancy Safety Studies, with recommendations on different methodologies that can be used in the postapproval setting to study the safety of drugs and biological products when used during pregnancy.
Healthcare
FDA Issues Guidance to Improve Collection of Pregnancy Safety Data for Drugs and Biologics
Source: FDA Press Releases — US Government, Public Domain